Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...
News Medical on MSN4h
How your brain learns from rewards might hold the key to treating depressionUsing computational models, the researchers studied how the brain’s reward-learning system functions in those with depression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback